Original Paper

Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 1, pp 53-59

First online:

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

  • Jun-ichi KitagawaAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Takeshi HaraAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Hisashi TsurumiAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine Email author 
  • , Naoe GotoAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Nobuhiro KanemuraAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Takeshi YoshikawaAffiliated withDivision of Hematology, Gifu Municipal Hospital
  • , Senji KasaharaAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Toshiki YamadaAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
  • , Michio SawadaAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
    • , Takeshi TakahashiAffiliated withDivision of Hematology, Gifu Municipal Hospital
    • , Masahito ShimizuAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine
    • , Tsuyoshi TakamiAffiliated withDepartment of Immunopathology, Gifu University Graduate School of Medicine
    • , Hisataka MoriwakiAffiliated withFirst Department of Internal Medicine, Gifu University Graduate School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

Patients and methods

We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.

Keywords

Peripheral T-cell lymphoma (PTCL) Soluble interleukin-2 receptor (sIL-2R) Prognostic analysis